Acetylsalicylic acid ( ASA ) did not reduce stroke or ‘ all cardiovascular events ’ compared to placebo in primary prevention patients with elevated BP and no prior cardiovascular disease .
To conclude for primary prevention in patients with elevated BP , antiplatelet therapy with ASA can not be recommended since the magnitude of benefit , a reduction in myocardial infa rct ion , is negated by a harm of similar magnitude , an increase in major haemorrhage .
Although elevated systemic blood pressure ( BP ) results in high intravascular pressure , the main complications of hypertension are related to thrombosis rather than haemorrhage .
It therefore seemed plausible that use of antithrombotic therapy may be useful in preventing thrombosis-related complications of elevated BP .
The objectives were to conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with BP , to address the following hypotheses : ( i ) antiplatelet agents reduce total deaths and /or major thrombotic events when compared to placebo or other active treatment ; and ( ii ) oral anticoagulants reduce total deaths and /or major thromboembolic events when compared to placebo or other active treatment .
Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist.
The safety and pharmacodynamic compatibility of clopidogrel with medications commonly used in patients with atherosclerosis , such as , a beta-adrenergic receptor antagonist ( atenolol ) and a calcium uptake inhibitor ( nifedipine ) were assessed . Atenolol and nifedipine interactions with clopidogrel were studied in patients with peripheral arterial obstructive disease taking a well-established regimen of nifedipine ( N group of 6 patients ) and in patients with coronary artery disease taking a well-established regimen of either atenolol ( A group of 8 patients ) or of atenolol and nifedipine ( AN group of 8 patients ) . The study was conducted as a double-blind , r and omized , crossover comparison of clopidogrel , 75 mg once daily , and placebo treatment for 7 days , with a 14-day washout between treatments . Pharmacodynamic interactions between atenolol and nifedipine , either alone or in combination , and clopidogrel were assessed primarily on the clinical control of angina or hypertension and , secondarily , by comparing the extent of inhibition of ADP ( 5 microM)-induced platelet aggregation achieved between the 3 groups . The mean number of anginal episodes per patient during the placebo week was 1.50 , 9.0 and 11.5 in the A , N and AN groups , respectively ; during the week of clopidogrel treatment , it was 1.39 , 7.3 and 9.0 , respectively , indicating no change in occurrence . Likewise , review of the use of nitrates ( long or short acting ) did not suggest any major change in usage during any period of the study . ECGs did not change between the three recording times ( at screening and at the end of each treatment period ) . Vital signs were also unchanged throughout . Percent inhibition of platelet aggregation on day 7 was 31 % in the N group , 39 % in the A group , 28 % in the AN group , and 33 % overall . In conclusion , the coadministration of clopidogrel did not interfere with the clinical control of hypertension or angina established with atenolol or nifedipine , or both . Clopidogrel retained its full antiplatelet effect , and there were no safety problems caused by the coadministration
Acetylsalicylic acid ( ASA ) did not reduce stroke or ‘ all cardiovascular events ’ compared to placebo in primary prevention patients with elevated BP and no prior cardiovascular disease .
To conclude for primary prevention in patients with elevated BP , antiplatelet therapy with ASA can not be recommended since the magnitude of benefit , a reduction in myocardial infa rct ion , is negated by a harm of similar magnitude , an increase in major haemorrhage .
Although elevated systemic blood pressure ( BP ) results in high intravascular pressure , the main complications of hypertension are related to thrombosis rather than haemorrhage .
It therefore seemed plausible that use of antithrombotic therapy may be useful in preventing thrombosis-related complications of elevated BP .
The objectives were to conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with BP , to address the following hypotheses : ( i ) antiplatelet agents reduce total deaths and /or major thrombotic events when compared to placebo or other active treatment ; and ( ii ) oral anticoagulants reduce total deaths and /or major thromboembolic events when compared to placebo or other active treatment .